# Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

> **NCT05436223** · PHASE2 · RECRUITING · sponsor: **Hrain Biotechnology Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- B-cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Human CD19Targeted T Cells Injection

## Key facts

- **NCT ID:** NCT05436223
- **Lead sponsor:** Hrain Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-09
- **Primary completion:** 2024-08-09
- **Final completion:** 2026-08-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05436223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05436223, "Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05436223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*